PL120131

PL120131 (32.0-33.4 μM) rescues Jurkat cells from PD-L1-induced apoptosis, reducing apoptotic signals by 25% with an IC₅₀ of 32.0 μM (Annexin V) and 33.4 μM (Caspase 3/7)^[2].
PL120131 (11.6 μM; 24 h) rescues primary mouse T-cells from apoptosis in 4T1 co-cultures, increases 4T1 cell death, and induces a significant, dose-dependent increase in Granzyme B production in CD3⁺/CD8⁺ T-cells^[2].
PL120131 (0.2-12.5 μg/mL; 24 h) induces dose-dependent increases in IFNγ and dose-dependent decreases in IL-12p70 and IL-10 in co-cultures of primary mouse lymphocytes and 4T1 cells, indicating activated T-cell function^[2].
PL120131 (30 μM; 30 min (Jurkat pre-treatment); 24 h (co-culture in microfluidics chip)) enables Jurkat cells to infiltrate a 3D MDA-MB-231 tumor environment, induce greater tumor cell death, and maintain higher Jurkat cell viability than anti-PD-1 antibody treatment^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.